CSL BEHRING ANNOUNCES FIRST TWO PATIENTS TREATED WITH HEMGENIX® (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY FOR HEMOPHILIA B IN EUROPE
Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMG…